This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers

Stocks in this article: MACK

CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two potential new therapies with a novel target – ErbB3, a signaling receptor believed to be responsible for triggering tumor growth and resistance in a number of malignancies including breast, ovarian, gastric, esophageal and bladder cancers. The two studies were presented in poster sessions at the European Society for Medical Oncology (ESMO) in Vienna, Austria.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/58387-merrimack-pharmaceuticals-erbb3-cancer-therapy-esmo-2012-congress

The separate studies were testing the safety profiles of (1) MM-121, developed in collaboration with Sanofi, in a combination regimen with weekly paclitaxel in advanced metastatic breast and ovarian cancers and (2) MM-111 in multiple HER2-Targeting regimens in advanced HER2 positive (ErbB2+ or HER2+) solid tumors.  Each study demonstrated a promising clinical benefit rate for the MM-121 and MM-111 combination regimens, a secondary endpoint for each of the studies.  MM-121 and MM-111 each employ their own unique mechanisms to stop ligand-driven activation of ErbB3 from signaling the cancer cell to grow.

"We are pleased to see signs of clinical benefit in our studies with MM-121 and MM-111 across a broad range of solid tumors in patients who have progressed on standard of care therapies," said Robert J. Mulroy, President and Chief Executive Officer, Merrimack Pharmaceuticals.  "Both candidates emerged from our Network Biology research engine, in which we identified ErbB3 as a central growth signaling node.  Given their unique approaches to targeting ErbB3 biology, we believe that MM-121 and MM-111 are important therapies to advance the treatment of cancer and we are excited to watch them progress through clinical development."

A Phase 1 Study of the Anti-ErbB3 Antibody MM-121 in Combination with Weekly Paclitaxel in Patients with Advanced Gynecologic and Breast Cancers (Abstract #: 974PD)

The study evaluated MM-121, a fully human monoclonal antibody, in combination with weekly paclitaxel, a standard regimen for patients with advanced gynecological and metastatic breast cancers.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs